![]() |
|
|
Vol. 58, Issue 4, 709-718, October 2000
Centre National de la Recherche Scientifique UMR 8532, Physico-chimie et Pharmacologie des Macromolécules Biologiques,
Institut Gustave Roussy, Villejuif, France
The new olivacine derivative S16020-2 (NSC-659687) is a DNA
topoisomerase II inhibitor endowed with a remarkable antitumor activity
against various experimental tumors. In vitro physicochemical properties of this compound, in particular its interaction with DNA and
DNA topoisomerase II, were very similar to those of ellipticine derivatives, except for a strictly ATP-dependent mechanism of cleavable
complex induction. From the Chinese hamster lung fibroblast cell line
DC-3F, a subline resistant to S16020-2, named DC-3F/S16, was selected
by adding stepwise increasing concentrations of the drug to the cell
growth medium. Whereas DC-3F/9-OH-E cells, a DC-3F subline
resistant to 9-hydroxy-ellipticine, are cross-resistant to S16020-2,
DC-3F/S16 cells are only very weakly cross-resistant to ellipticine
derivatives, indicating that, despite their structural similarity,
these compounds may differ in their mechanisms of action. Uptake and
efflux rates of S16020-2 were identical in the resistant and the
sensitive cells. Topoisomerase II
was expressed at the same level in
both sensitive and resistant cells, whereas expression of the
-enzyme was approximately 50% lower in the resistant cells.
Sequencing of both
- and
-isoform cDNAs revealed a point mutation
that converts Arg486 to a Gly in the
cDNA, whereas the
cDNA was not modified. This amino acid substitution in a highly
conserved sequence of the enzyme appears to be responsible for the
resistance to S16020-2. Comparative analysis of the properties of the
ellipticine and S16020-2-resistant cells suggests that S16020-2, which
is a DNA intercalator, might also interact with this enzyme amino acid sequence through its side chain.
This article has been cited by other articles:
![]() |
Y. Chen, Y. Tang, M.-T. Wang, S. Zeng, and D. Nie Human Pregnane X Receptor and Resistance to Chemotherapy in Prostate Cancer Cancer Res., November 1, 2007; 67(21): 10361 - 10367. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Kang and I. K. Chung Down-Regulation of DNA Topoisomerase IIalpha in Human Colorectal Carcinoma Cells Resistant to a Protoberberine Alkaloid, Berberrubine Mol. Pharmacol., April 1, 2002; 61(4): 879 - 884. [Abstract] [Full Text] [PDF] |
||||